Abbott Laboratories (NYSE:ABT) on Wednesday reported first-quarter sales of $10.36 billion, up 7.2% year over year, almost in line with the consensus of $10.40 billion.
First-quarter sales increased 4% on a reported basis, 6.9% on an organic basis, or 8.3% when excluding COVID-19 testing-related sales.
The U.S. MedTech giant reported adjusted EPS of $1.09, beating the consensus of $1.07 and the management guidance of $1.05-$1.09.
“Once again, Abbott’s diversified business model delivered top-tier sales and EPS growth,” said Robert Ford, chairman and CEO of Abbott. “It is this diversification and execution that allows Abbott to navigate through periods of uncertainty and continually deliver sustainable growth.”
Also Read: Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom
Medical Device sales increased 9.9% to $4.89 billion with organic growth of 12.6%, led by Diabetes Care, Structural Heart, Heart Failure …
Full story available on Benzinga.com
Abbott Laboratories (NYSE:ABT) on Wednesday reported first-quarter sales of $10.36 billion, up 7.2% year over year, almost in line with the consensus of $10.40 billion.
First-quarter sales increased 4% on a reported basis, 6.9% on an organic basis, or 8.3% when excluding COVID-19 testing-related sales.
The U.S. MedTech giant reported adjusted EPS of $1.09, beating the consensus of $1.07 and the management guidance of $1.05-$1.09.
“Once again, Abbott’s diversified business model delivered top-tier sales and EPS growth,” said Robert Ford, chairman and CEO of Abbott. “It is this diversification and execution that allows Abbott to navigate through periods of uncertainty and continually deliver sustainable growth.”
Also Read: Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom
Medical Device sales increased 9.9% to $4.89 billion with organic growth of 12.6%, led by Diabetes Care, Structural Heart, Heart Failure …
Full story available on Benzinga.com
Abbott Laboratories (NYSE:ABT) on Wednesday reported first-quarter sales of $10.36 billion, up 7.2% year over year, almost in line with the consensus of $10.40 billion.
First-quarter sales increased 4% on a reported basis, 6.9% on an organic basis, or 8.3% when excluding COVID-19 testing-related sales.
The U.S. MedTech giant reported adjusted EPS of $1.09, beating the consensus of $1.07 and the management guidance of $1.05-$1.09.
“Once again, Abbott’s diversified business model delivered top-tier sales and EPS growth,” said Robert Ford, chairman and CEO of Abbott. “It is this diversification and execution that allows Abbott to navigate through periods of uncertainty and continually deliver sustainable growth.”
Also Read: Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom
Medical Device sales increased 9.9% to $4.89 billion with organic growth of 12.6%, led by Diabetes Care, Structural Heart, Heart Failure …Full story available on Benzinga.com Read MoreABT, Briefs, Earnings, Large Cap, News, Stories That Matter, why it’s moving, Guidance, Health Care, Top Stories, Movers, General, ABT, US0028241000, News, Earnings, Large Cap, Guidance, Health Care, Top Stories, Movers, General, Benzinga News
